Key result
Ranolazine, an inhibitor of the late inward sodium current, shows experimental and preliminary clinical evidence as a potential therapeutic strategy for a broad spectrum of cardiac arrhythmias.
Why the study?
Does ranolazine have efficacy and safety in treating a broad spectrum of cardiac arrhythmias?
Does ranolazine have efficacy and safety in treating a broad spectrum of cardiac arrhythmias?
Ranolazine, an approved antianginal drug, shows experimental and preliminary clinical promise as a novel antiarrhythmic agent through inhibition of the late inward sodium current.
Premature for arrhythmia management; leaves open efficacy pending dedicated randomized trials.
Ranolazine is an agent approved for the symptomatic treatment of chronic stable angina that inhibits the late inward sodium current (I(NaL)). I(NaL) amplitude is increased under several pathological conditions, including increased oxidative stress, myocardial ischemia, cardiac hypertrophy, heart failure, long-QT syndrome variant 3 and atrial fibrillation. Experimental and preliminary clinical evidence suggests that ranolazine may represent a new therapeutic strategy in the treatment of a broad spectrum of cardiac arrhythmias. This article reviews the role of the I(NaL) and provides an update on experimental and clinical evidence supporting the efficacy and safety of ranolazine across a broad spectrum of arrhythmias.
No takes yet. Share an insight, caveat, or question.
Tamargo et al. (2011) conducted a review in Cardiac arrhythmias. Ranolazine was evaluated. Ranolazine, an inhibitor of the late inward sodium current, shows experimental and preliminary clinical evidence as a potential therapeutic strategy for a broad spectrum of cardiac arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: